Bioactive mesoporous silica materials-assisted cancer immunotherapy

Jiali Liu; Jiying Liu; Yaxin Wang; Fangman Chen; Yan He; Xiaochun Xie; Yiling Zhong; Chao Yang

doi:10.1016/j.biomaterials.2024.122919

Bioactive mesoporous silica materials-assisted cancer immunotherapy

Biomaterials. 2024 Oct 25:315:122919. doi: 10.1016/j.biomaterials.2024.122919. Online ahead of print.

Authors

Jiali Liu¹, Jiying Liu², Yaxin Wang³, Fangman Chen⁴, Yan He⁵, Xiaochun Xie⁴, Yiling Zhong⁶, Chao Yang⁷

Affiliations

¹ Department of Orthopedics, Academy of Orthopedics-Guangdong Province, Orthopedic Hospital of Guangdong Province, Guangdong Provincial Key Laboratory of Bone and Joint Degenerative Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong, 511442, China.
² Department of Chemistry, University of Michigan, Ann Arbor, MI, 48109, USA.
³ School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong, 511442, China.
⁴ National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangdong, 510006, China.
⁵ School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong, 511442, China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangdong, 510006, China.
⁶ College of Pharmacy, State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, 511443, China. Electronic address: [email protected].
⁷ Department of Orthopedics, Academy of Orthopedics-Guangdong Province, Orthopedic Hospital of Guangdong Province, Guangdong Provincial Key Laboratory of Bone and Joint Degenerative Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China. Electronic address: [email protected].

PMID: 39481339
DOI: 10.1016/j.biomaterials.2024.122919

Abstract

Immunotherapy is initially envisioned as a powerful approach to train immune cells within the tumor microenvironment (TME) and lymphoid tissues to elicit strong anti-tumor responses. However, clinical cancer immunotherapy still faces challenges, such as limited immunogenicity and insufficient immune response. Leveraging the advantages of mesoporous silica (MS) materials in controllable drug and immunomodulator release, recent efforts have focused on engineering MS with intrinsic immunoregulatory functions to promote robust, systemic, and safe anti-tumor responses. This review discusses advances in bioactive MS materials that address the challenges of immunotherapy. Beyond their role in on-demand delivery and drug release in response to the TME, we highlight the intrinsic functions of bioactive MS in orchestrating localized immune responses by inducing immunogenic cell death in tumor cells, modulating immune cell activity, and facilitating tumor-immune cell interactions. Additionally, we emphasize the advantages of bioactive MS in recruiting and activating immune cells within lymphoid tissues to initiate anti-tumor vaccination. The review also covers the challenges of MS-assisted immunotherapy, potential solutions, and future outlooks. With a deeper understanding of material-bio interactions, the rational design of MS with sophisticated bioactivities and controllable responsiveness holds great promise for enhancing the outcomes of personalized immunotherapy.

Keywords: Bioactive; Immunotherapy; Lymphoid tissue; Mesoporous silica; Tumor microenvironment.

Publication types

Review